For patients with locally advanced, ALK fusion-positive NSCLC, multiple studies (80, 81) have indicated that immunotherapy provides suboptimal efficacy benefits in ALK fusion populations, whereas targeted therapy has demonstrated superior clinical effectiveness. The gene discussed is ALK; the disease is non-small cell lung carcinoma.